Egetis Therapeutics AB (OSTO:PLED BTA) Debt-to-Asset : 0.14 (As of Mar. 2025)

Egetis Therapeutics AB Debt-to-Asset Chart

Egetis Therapeutics AB Annual Data
	Trend	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23	Dec24
Debt-to-Asset		Get a 7-Day Free Trial					0.01	0.01	0.01	0.15	0.15

Egetis Therapeutics AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Debt-to-Asset	Get a 7-Day Free Trial															0.17	0.17	0.19	0.15	0.14

Competitive Comparison of Egetis Therapeutics AB's Debt-to-Asset

For the Biotechnology subindustry, Egetis Therapeutics AB's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Egetis Therapeutics AB's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Egetis Therapeutics AB's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Egetis Therapeutics AB's Debt-to-Asset falls into.

Egetis Therapeutics AB Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Egetis Therapeutics AB's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Egetis Therapeutics AB's Debt-to-Asset for the quarter that ended in Mar. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Egetis Therapeutics AB  (OSTO:PLED BTA) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Egetis Therapeutics AB Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Egetis Therapeutics AB's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Egetis Therapeutics AB Business Description